C polpharma DRUG EXPOSURE DURING PREGNANCY – PREGNANCY AND POSTPARTUM FORM					
Pr	regnant wome	n		v 2. 21.08.2020	
	PRELIMINARY	SUPPLEMEN	ITARY		
on date					
rmation:					
tient	Primary Care Physicia	เท	Gyneco	ologist/Obstetriciar	
n 🗌	Other (please specif	у)			
DATA OF PA	TIENT EXPOSED T	O DRUG DURI	NG PREGNANC	CY	
Country where drug exposure in pregnancy occurred	Patient's DOB DD/MM/YY	Patient's age at the time of drug exposure in pregnancy	Weight	Height	
evious pregnanc	ies				
lications occur d mancies?	uring	YES*	NO		
detailed information of	n irregularities during pregnai	ncy, including the stage o	of pregnancy when comp	olications occurred:	
ical history	heart diseases, asthma	a, allergies, depression o	or other mental disorders		
	Pr On date Trmation: tient DATA OF PA Country where drug exposure in pregnancy occurred evious pregnanct lications occur d gnancies? detailed information of	PREGNANCY A Pregnant wome PRELIMINARY PRELIMINARY PRELIMINARY Primary Care Physicia Other (please specified Other (please specified Other (please specified Other (please specified DD/MM/YY Other (please specified DD/MM/YY evious pregnancies Ilications occur during gnancies? detailed information on irregularities during pregnancies Ilications occur during gnancies? Please enter the past of heart diseases, asthmetice	PREGNANCY AND POSTPART Pregnant women PRELIMINARY SUPPLEMEN on date rmation: tient Primary Care Physician Other (please specify) DATA OF PATIENT EXPOSED TO DRUG DURI Country where drug exposure in pregnancy DD/MM/YY Patient's DOB DD/MM/YY Patient's age at the time of drug exposure in pregnancy evious pregnancies lications occur during mancies? Please enter the past or current diseases such heart diseases, asthma, allergies, depression or	PREGNANCY AND POSTPARTUM FORM Pregnant women PRELIMINARY SUPPLEMENTARY PRELIMINARY SUPPLEMENTARY PRELIMINARY Care Physician Primary Care Physician Other (please specify) DATA OF PATIENT EXPOSED TO DRUG DURING PREGNANC Country where drug exposure in pregnancy DD/MM/YY Patient's age at the time of drug exposure in pregnancy Patient's DOB DD/MM/YY Patient's age at the time of drug exposure in pregnancy Veight Veig	

II. INFORMATION ABOUT THE CURRENT PREGNANCY (OR FETUS IN CASE OF PLANNED TERMINATION OR MISCARRIAGE – PLEASE COMPLETE PART III)						
1. Date of last menstruation						
2. Current gestational age						
3. Gestational age at the time of patient exposure to drug						
	ated <i>(e.g. GTD</i>), describe with dates:					
5. Estimated delivery date						
6. Please specify the multiplicity of pregnancy (e.g. single preg	nancy, twin pregnancy)					
7. If infertility was treated, please describe the treatment						

III. INFORMATION ABOUT THE FETUS

(IN CASES OF PLANNED TERMINATION	N OF PREGNANCY OR MISCARRIAGE)
1. Reason for termination	
2. Gestational age at termination	
3. Results of physical examination of the child (sex, deter	cted fetal malformations)

IV. INFORMATION ON EXPOSURE DURING PREGNANCY

Please provide details about the medicinal products, herbal products and dietary supplements (e.g. vitamin supplements) used during pregnancy.

Full product name (with dose)	Batch number/ Expiry date	Dosage regimen	Single dose	ministr (e.g. ora	ıl, sublin- traveno-	Treatment start date dd mm yy	end	atment date mm yy		rapeutic cation
1. Did you exper taking the above	ience any a described <u>(</u>	dverse events <u>lrugs</u> ?	after		YES*			NO		
*If yes, please pr	ovide the foll	owing informatio	on:							
Drug name		Adverse e	event		Seriou (** If se	of reactions s/Non-seriou rious, specify to put of those give c)	he	Start date dd mm [•]	уу	End date dd mm yy
** Type of reaction: • death <i>(please speci</i> bility or incapacity, •	fy the cause of	<i>death)</i> , • hospitali	zation (<i>more than</i>	2 days) c	or extende					
Description o	f adverse ev	vent:								

iD. or	he patient smoke cigarettes, consume alcohol YES* NO	
	s, specify the type of stimulants, amount and frequency of use:	
. Pa	illnesses that occurred during pregnancy (e.g. flu)	
••••		
Se	ogical test results <i>(e.g. rubella, toxoplasmosis)</i>	

5. Test	results during pregnancy (please	e specify whether the resu	It was normal if the information is available):
Test name	;	Test date	Test result
ULTRAS	OUND		
Doppler	ultrasound		
Materna	l blood pressure		
CBC			
Liver tes	ts (AST, ALT)		
Urinalysi	s (e.g. creatinine, urea)		
Uterine	artery flows		
Cervical	length		
Serum n	narkers (AFP and others)		
Chorioni	c villus sampling (CVS)		
Amnioc	entesis		
Other			
Other			
Family	y medical history history of congenital malformations (rent and the person with the defect)	determination of relationship –	with the mother/father, determination of kinship between

V. INFORMATION ABOUT THE CHILD'S FATHER	
1. DOB	
2. Medical history Please describe the past or current diseases, e.g. hypertension, diabetes mellitus, epilepsy, heart diseases, asthma, aller depression or other mental disorders, sexually transmitted diseases, hepatitis <i>(type)</i> , viral infections <i>(specify)</i> , AIDS.	gies,
3. Chronically used drugs at the time of conception Please specify all drugs taken (name, dose, dosage form, dosage regimen, duration of treatment, indications).	
VI. REPORTING PERSON'S DETAILS	
1. Full name	
2. Correspondence address	
3. Contact phone number	
4. Email	
5. Medical specialty (if the reporting person is a medical practitioner)	Stamp
6. Do you agree to be contacted again to obtain supplementary information, if needed?	
*If yes, please indicate the preferred route of contact:	
phone e-mail	
Medical Department, Zakłady Farmaceutyczne POLPHARMA S.A. 6 Bobrowiecka Street, 00-728 Warsaw, Poland, email: phv@polpharma.com	P. 6

6 Bobrowiecka Street, 00-728 Warsaw, Poland, email: phv@polpharma.com

PATIENT INFORMATION REGARDING THE GDPR IS BELOW. If you are a healthcare professional, go to page 8 and read the information regarding the GDPR.

On the basis of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as: "GDPR"), we hereby inform that:

[Controller, data protection officer, contact details]

- The Controller of your personal data is the Marketing Authorization Holder of the medicinal product which is the subject of the notification, i.e.:

 Zakłady Farmaceutyczne POLPHARMA S.A. with its registered office in Starogard Gdański (83-200) at ul. Pelplińska 19. (hereinafter referred to as the "Controller").
- You can contact the Controller in writing to the above addresses. The Controller has appointed a Data Protection Officer, whom you may contact in all matters relating to the personal data protection, by writing to: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) Bobrowiecka 6, 00-728 Warszawa, by sending an e-mail to: dpo@polpharma.com or by telephone on: 22 364 63 11.
- Where an adverse event has occurred following the use of a medicinal product, the adverse event may be reported to the Medical Department, address: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) ul. Bobrowiecka 6, 00 -728 Warszawa, tel.: 22 364 61 00, email: phv@polpharma.com.

[Purpose and legal basis for personal data processing]

4. Your personal data will be processed:

- a. for the purpose necessary for ensuring high standards of quality and safety of medicinal products by Controller and, in particular, monitoring the safety of medicinal products, including the keeping of records of individual adverse events to medicinal products and the reporting of individual adverse events to medicinal products to the competent authorities– on the basis of:
 - data concerning health will be processed pursuant to Article 9(2)(i) of the GDPR, i.e. processing is necessary for reasons related to the public interest in the field of public health in the form of ensuring high standards of quality and safety of medicinal products pursuant to the provisions of law, i.e. pursuant to Article 36e(1) of the Polish Pharmaceutical Law Act;
 - other personal data will be processed pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on the Controller pursuant to Article 36e(1) of the Pharmaceutical Law Act;
- b. contacting the attending physician and obtaining additional information from the attending physician in connection with adverse events to the medicinal product pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on the Controller pursuant to Article 36e(1) of the Pharmaceutical Law Act;
- c. determination, investigation or defence of possible claims between you and the Administrator with regard to health data pursuant to Article 9(2)(b) of the GDPR, i.e. processing is necessary for the determination, investigation or defence of claims; in the case of other personal pursuant to Article 6(1)(f) of the GDPR, i.e. on the basis of the legitimate interest pursued by the Administrator, which is the possibility to pursue claims.
- 5. You will not be subject to automated decision-making, including decisions based on profiling.
- 6. Provision of Your personal data is voluntary.

[Categories of personal data recipients]

- 7. Your personal data may be disclosed to the following entities: attending physician (if consent is granted to contact with the attending physician), employees, IT service providers, providers of consulting and legal services.
- 8. Your personal data may be made available to entities and bodies authorized to process such data under the law, in particular to the President of the Office of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency and other competent authorities of the Member States of the European Union, in which the Controller has obtained a marketing authorisation for a medicinal product.
- 9. The Controller does not intend to transfer your personal data outside the European Economic Area or to an international organisation.

[Personal data storage period]

- 10. Your personal data shall be processed for the period necessary to achieve the purposes for which the data are processed or until an objection is raised (if the processing is based on the legitimate interest of the Controller) or until the withdrawal of consent (if the processing is based on the given consent) depending on which of the events occurs earlier.
- 11. After the expiry of the aforementioned period, personal data shall be stored for 10 years from the expiry date of the medicinal product series to which the application referred or until the claims expiry or until you have objected to the processing (if the processing is based on legitimate interest of the Controller) or have withdrawn your consent (if the processing is based on consent) whichever occurs first.

[Rights]

- 12. You have the right to:
 - a. access to data concerning you, the right of rectification, erasure, restriction of processing, the right to object to the processing of data;
 b. transfer personal data, i.e. to receive from the controller personal data in a structured, commonly used machine-readable format;
 - c. to the extent that the processing of your personal data is based on consent, the right to withdraw consent to the processing of your personal data at any time. The withdrawal of consent shall not affect the lawfulness of the processing carried out on the basis of consent prior to its withdrawal.
- 13. In order to exercise the above rights, you need to contact the Controller or the Data Protection Officer, using the aforementioned contact details (contact details provided above).
- 14. You also have the right to lodge a complaint with a personal data protection supervisory authority (President of the Personal Data Protection Office), if you believe that the data processing violates the GDPR.

HEALTHCARE PROFESSIONAL INFORMATION REGARDING THE GDPR IS BELOW. If you are a Patient, go to page 7 and read the information regarding the GDPR.

On the basis of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as: "GDPR"), we hereby inform that:

[Controller, data protection officer, contact details]

- The Controller of your personal data is the Marketing Authorization Holder of the medicinal product which is the subject of the notification, i.e.:

 Zakłady Farmaceutyczne Polpharma S.A. with its registered office in Starogard Gdański (83-200) at ul. Pelplińska 19 (hereinafter referred to as the "Controller").
- You can contact the Controller in writing to the above addresses. The Controller has appointed a Data Protection Officer, whom you may contact in all matters relating to the personal data protection, by writing to Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) Bobrowiecka 6, 00-728 Warszawa, by sending an e-mail to: dpo@polpharma.com or by telephone on: 22 364 63 11.
- Where an adverse event has occurred following the use of a medicinal product, the adverse event may be reported to Medical Department, adress: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw), ul. Bobrowiecka 6, 00 -728 Warszawa, tel.: 22 364 61 00, email: phv@polpharma.com.

[Purpose and legal basis for personal data processing]

4. Your personal data will be processed:

- a. for the purpose necessary for the Controller's ensuring high standards of quality and safety of medicinal products and, in particular, monitoring the safety of medicinal products, including the keeping of records of individual adverse events to medicinal products and the reporting of individual adverse events to medicinal products to the competent authorities– on the basis of:
 - personal data, including the name and surname and address of the medical profession of the person reporting the adverse event of
 a medicinal product pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on
 the Controller pursuant to Article 36e(1)(2) and (3) of the Polish Pharmaceutical Law, also pursuant to Article 9 (2) (i) GDPR;
- **b.** determination, investigation or defence of potential claims between you and the Controller basis of Article 6(1)(f) of the GDPR, i.e. on the basis of the legitimate interest pursued by the Controller, which is the possibility to pursue claims.
- 5. You will not be subject to automated decision-making, including decisions based on profiling.
- 6. Provision of Your personal data is obligatory.

[Categories of personal data recipients]

- 7. Your personal data may be disclosed to the following entities: employees, IT service providers, providers of consulting and legal services.
- 8. Your personal data may be made available to entities and bodies authorized to process such data under the law, in particular to the President of the Office of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency and other competent authorities of the Member States of the European Union, in which the Controller has obtained a marketing authorisation for a medicinal product.
- 9. The Controller does not intend to transfer your personal data outside the European Economic Area or to an international organisation.

[Personal data storage period]

- 10. Your personal data shall be processed for the period necessary to achieve the purposes for which the data are processed or until an objection is raised (if the processing is based on the legitimate interest of the Controller) or until the withdrawal of consent (if the processing is based on the given consent) depending on which of the events occurs earlier.
- 11. After the expiry of the aforementioned period, personal data shall be stored for 10 years from the expiry date of the medicinal product series to which the application referred or until the claims expiry or until you have objected to the processing (if the processing is based on legitimate interest of the Controller) or have withdrawn your consent (if the processing is based on consent) whichever occurs first.

[Rights]

12. You have the right to:

- a. access to data concerning you, the right of rectification, erasure, restriction of processing, the right to object to the processing of data;
- b. transfer personal data, i.e. to receive from the controller personal data in a structured, commonly used machine-readable format;
- c. to the extent that the processing of your personal data is based on consent, the right to withdraw consent to the processing of your personal data at any time. The withdrawal of consent shall not affect the lawfulness of the processing carried out on the basis of consent prior to its withdrawal.
- 13. In order to exercise the above rights, you need to contact the Controller or the Data Protection Officer, using the aforementioned contact details (contact details provided above).
- 14. You also have the right to lodge a complaint with a personal data protection supervisory authority (President of the Personal Data Protection Office), if you believe that the data processing violates the GDPR.

Postpartum women

PART B

REPORT	PRELIMINARY SU	IPPLEMENTARY
Report completion date DD/MM/YY		
Source of information	on:	
Pregnant patient	Primary Care Physician	Gynecologist/Obstetrician
Pediatrician	Other (please specify)	

If PART A of the report has been completed in the previous submission, please complete ONLY sections IV to VI. Please enter additional information, if needed, supplementing the previous report in sections I to III.

<u> </u>	DATA OF PATIE			NG PREGNANC	Υ
Patient initials	Country where drug exposure in pregnancy occurred	Patient's DOB DD/MM/YY	Patient's age at the time of drug exposure in pregnancy	Weight	Height
1. Number of pre	evious pregnancies				
2. Did any compl			YES*	NO	
* If yes, please provide	detailed information on in	regularities during pregna	ancy, including the stage o	of pregnancy when comp	lications occurred:
3. Patient's medi	cal history	heart diseases, asthma	or current diseases such a, allergies, depression o pe), viral infections (speci	r other mental disorders	
Medical Department,	Zakłady Farmaceutyc 00-728 Warsaw, Polanc	zne POLPHARMA S.A.	ma com		P. 9

II. INFORMATION ON EXPOSURE DURING PREGNANCY

Please provide details about the medicinal products, herbal products and dietary supplements (e.g. vitamin supplements) used during pregnancy.

Full product name (with dose)	Batch number/ Expiry date	Dosage regimen	Single dose	Route of ad- ministration (e.g. oral, sublin- gual, intraveno- us, etc)	Treatment start date dd mm yy	Treatment end date dd mm yy	Therapeutic indication
1. Did you exper after taking th	ience any a 1e above-de	dverse events scribed <u>drugs</u>	<u>;</u> ?	YES*		NO	
*lf yes, please cor	mplete the info	rmation below:					
Drug name		Adverse	event	Serio (** if s	s of reactions us/Non-seriou erious, specify t out of those give v)	he dd mm	End date dd mm yy
** Type of reaction: • death <i>(please speci</i> bility or incapacity, •	ify the cause of	death), • hospitali	ization <i>(more than</i>	2 days) or extend			
Description of	f adverse ev	/ent:					

	III. INFORMATION	ABOUT THE CHILD'S FATHER
DOB		
Medical Please describe the pa depression or other n	ast or current diseases, e.g. hyperter nental disorders, sexually transmit	history nsion, diabetes mellitus, epilepsy, heart diseases, asthma, allergies, ted diseases, hepatitis (type), viral infections (specify), AIDS.
Chronically used Please specify all dru	drugs at the time of concept ags taken (name, dose, dosage form	tion n, dosage regimen, duration of treatment, indications).
Chronically used Please specify all dru	drugs at the time of concept ags taken (name, dose, dosage forn	tion n, dosage regimen, duration of treatment, indications).
Chronically used Please specify all dru	drugs at the time of concept ugs taken (name, dose, dosage forn	tion n, dosage regimen, duration of treatment, indications).
Chronically used Please specify all dru	ugs taken (name, dose, dosage forn	tion n, dosage regimen, duration of treatment, indications). TION ABOUT DELIVERY
Please specify all dru	ugs taken (name, dose, dosage forn	n, dosage regimen, duration of treatment, indications).
Please specify all dru Delivery date	IV. INFORMA	n, dosage regimen, duration of treatment, indications).
Please specify all dru Delivery date Delivery method	IV. INFORMA	n, dosage regimen, duration of treatment, indications). TION ABOUT DELIVERY
Please specify all dru Delivery date Delivery method	IV. INFORMA	n, dosage regimen, duration of treatment, indications). TION ABOUT DELIVERY cesarean section complicated (e.g. GTD),
Please specify all dru Delivery date Delivery method	IV. INFORMA	n, dosage regimen, duration of treatment, indications). TION ABOUT DELIVERY cesarean section complicated (e.g. GTD),
 Chronically used Please specify all dru Delivery date Delivery method Course of pregna 	IV. INFORMA	n, dosage regimen, duration of treatment, indications). TION ABOUT DELIVERY cesarean section complicated (e.g. GTD),

Medical Department, Zakłady Farmaceutyczne POLPHARMA S.A. 6 Bobrowiecka Street, 00-728 Warsaw, Poland, email: phv@polpharma.com

4. Course of delivery	Course of delivery normal delivery, scheduled delivery (e.g. pretodelivery) * complicated delivery (e.g. pretodelivery)					
*If any complications occurred d	luring delivery, please provide detail	ed information:				
	V. INFORMATION A	BOUT THE NEWBORN				
1. Gestational age at del	ivery					
2. DOB	·	3. Initials				
4. Child's gender	female	male				
5. Results of the child's p	physical examination on the	day of birth:				
WEIGHT	LENGTH	HEAD CIRCUMFERENCE	APGAR SCORE			
6. Were malformations c	liagnosed at birth?	YES*	NO			
*If yes, please provide c	detailed information					
n jee, please plettae e						
7. Does the child have a	chronic disease?	YES*	NO			
*If yes, please provide (detailed information (type of di	isease, treatment used):				
Medical Denartment Zakładu	Farmaceutyczne POLPHARMA S.	٨	P. 12			

8. Did or does your child take any medications? (name, dose, dosage form, dosage regimen, duration of treatment, indications):	YES* NO
*If yes, please provide detailed information (type of disease	treatment used):
	, ireaiment useuj.

VI. REPORTING PERSON'S DETAILS		
1. Full name		
2. Correspondence a	ddress	

3. Contact phone number

4. Email

5. Medical specialty (if the reporting person is a medical practitioner)		Stamp	
6. Do you agree to be contacted again to obtain supplementary information, if needed?	YES*	NO	
*If yes, please indicate the preferred route of contact:			
Medical Department, Zakłady Farmaceutyczne POLPHARMA S.A. 6 Bobrowiecka Street 00-728 Warsaw, Poland email: phy@polpharma.com			P. 13

PATIENT INFORMATION REGARDING THE GDPR IS BELOW. If you are a healthcare professional, go to page 15 and read the information regarding the GDPR.

On the basis of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as: "GDPR"), we hereby inform that:

[Controller, data protection officer, contact details]

- The Controller of your personal data is the Marketing Authorization Holder of the medicinal product which is the subject of the notification, i.e.:

 Zakłady Farmaceutyczne POLPHARMA S.A. with its registered office in Starogard Gdański (83-200) at ul. Pelplińska 19. (hereinafter referred to as the "Controller").
- You can contact the Controller in writing to the above addresses. The Controller has appointed a Data Protection Officer, whom you may contact in all matters relating to the personal data protection, by writing to: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) Bobrowiecka 6, 00-728 Warszawa, by sending an e-mail to: dpo@polpharma.com or by telephone on: 22 364 63 11.
- Where an adverse event has occurred following the use of a medicinal product, the adverse event may be reported to the Medical Department, address: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) ul. Bobrowiecka 6, 00 -728 Warszawa, tel.: 22 364 61 00, email: phv@polpharma.com.

[Purpose and legal basis for personal data processing]

4. Your personal data will be processed:

- a. for the purpose necessary for ensuring high standards of quality and safety of medicinal products by Controller and, in particular, monitoring the safety of medicinal products, including the keeping of records of individual adverse events to medicinal products and the reporting of individual adverse events to medicinal products to the competent authorities– on the basis of:
 - data concerning health will be processed pursuant to Article 9(2)(i) of the GDPR, i.e. processing is necessary for reasons related to the public interest in the field of public health in the form of ensuring high standards of quality and safety of medicinal products pursuant to the provisions of law, i.e. pursuant to Article 36e(1) of the Polish Pharmaceutical Law Act;
 - other personal data will be processed pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on the Controller pursuant to Article 36e(1) of the Pharmaceutical Law Act;
- b. contacting the attending physician and obtaining additional information from the attending physician in connection with adverse events to the medicinal product pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on the Controller pursuant to Article 36e(1) of the Pharmaceutical Law Act;
- c. determination, investigation or defence of possible claims between you and the Administrator with regard to health data pursuant to Article 9(2)(b) of the GDPR, i.e. processing is necessary for the determination, investigation or defence of claims; in the case of other personal pursuant to Article 6(1)(f) of the GDPR, i.e. on the basis of the legitimate interest pursued by the Administrator, which is the possibility to pursue claims.
- 5. You will not be subject to automated decision-making, including decisions based on profiling.
- 6. Provision of Your personal data is voluntary.

[Categories of personal data recipients]

- 7. Your personal data may be disclosed to the following entities: attending physician (if consent is granted to contact with the attending physician), employees, IT service providers, providers of consulting and legal services.
- 8. Your personal data may be made available to entities and bodies authorized to process such data under the law, in particular to the President of the Office of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency and other competent authorities of the Member States of the European Union, in which the Controller has obtained a marketing authorisation for a medicinal product.
- 9. The Controller does not intend to transfer your personal data outside the European Economic Area or to an international organisation.

[Personal data storage period]

- 10. Your personal data shall be processed for the period necessary to achieve the purposes for which the data are processed or until an objection is raised (if the processing is based on the legitimate interest of the Controller) or until the withdrawal of consent (if the processing is based on the given consent) depending on which of the events occurs earlier.
- 11. After the expiry of the aforementioned period, personal data shall be stored for 10 years from the expiry date of the medicinal product series to which the application referred or until the claims expiry or until you have objected to the processing (if the processing is based on legitimate interest of the Controller) or have withdrawn your consent (if the processing is based on consent) whichever occurs first.

[Rights]

- 12. You have the right to:
 - a. access to data concerning you, the right of rectification, erasure, restriction of processing, the right to object to the processing of data;
 b. transfer personal data, i.e. to receive from the controller personal data in a structured, commonly used machine-readable format;
 - c. to the extent that the processing of your personal data is based on consent, the right to withdraw consent to the processing of your personal data at any time. The withdrawal of consent shall not affect the lawfulness of the processing carried out on the basis of consent prior to its withdrawal.
- 13. In order to exercise the above rights, you need to contact the Controller or the Data Protection Officer, using the aforementioned contact details (contact details provided above).
- 14. You also have the right to lodge a complaint with a personal data protection supervisory authority (President of the Personal Data Protection Office), if you believe that the data processing violates the GDPR.

HEALTHCARE PROFESSIONAL INFORMATION REGARDING THE GDPR IS BELOW. If you are a Patient, go to page 14 and read the information regarding the GDPR.

On the basis of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as: "GDPR"), we hereby inform that:

[Controller, data protection officer, contact details]

- The Controller of your personal data is the Marketing Authorization Holder of the medicinal product which is the subject of the notification, i.e.:

 Zakłady Farmaceutyczne Polpharma S.A. with its registered office in Starogard Gdański (83-200) at ul. Pelplińska 19 (hereinafter referred to as the "Controller").
- 2. You can contact the Controller in writing to the above addresses. The Controller has appointed a Data Protection Officer, whom you may contact in all matters relating to the personal data protection, by writing to Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) Bobrowiecka 6, 00-728 Warszawa, by sending an e-mail to: **dpo@polpharma.com** or by telephone on: **22 364 63 11**.
- Where an adverse event has occurred following the use of a medicinal product, the adverse event may be reported to Medical Department, adress: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw), ul. Bobrowiecka 6, 00 -728 Warszawa, tel.: 22 364 61 00, email: phv@polpharma.com.

[Purpose and legal basis for personal data processing]

4. Your personal data will be processed:

- a. for the purpose necessary for the Controller's ensuring high standards of quality and safety of medicinal products and, in particular, monitoring the safety of medicinal products, including the keeping of records of individual adverse events to medicinal products and the reporting of individual adverse events to medicinal products to the competent authorities– on the basis of:
 - personal data, including the name and surname and address of the medical profession of the person reporting the adverse event of
 a medicinal product pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on
 the Controller pursuant to Article 36e(1)(2) and (3) of the Polish Pharmaceutical Law, also pursuant to Article 9 (2) (i) GDPR;
- **b.** determination, investigation or defence of potential claims between you and the Controller basis of Article 6(1)(f) of the GDPR, i.e. on the basis of the legitimate interest pursued by the Controller, which is the possibility to pursue claims.
- 5. You will not be subject to automated decision-making, including decisions based on profiling.
- 6. Provision of Your personal data is obligatory.

[Categories of personal data recipients]

- 7. Your personal data may be disclosed to the following entities: employees, IT service providers, providers of consulting and legal services.
- 8. Your personal data may be made available to entities and bodies authorized to process such data under the law, in particular to the President of the Office of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency and other competent authorities of the Member States of the European Union, in which the Controller has obtained a marketing authorisation for a medicinal product.
- 9. The Controller does not intend to transfer your personal data outside the European Economic Area or to an international organisation.

[Personal data storage period]

- 10. Your personal data shall be processed for the period necessary to achieve the purposes for which the data are processed or until an objection is raised (if the processing is based on the legitimate interest of the Controller) or until the withdrawal of consent (if the processing is based on the given consent) depending on which of the events occurs earlier.
- 11. After the expiry of the aforementioned period, personal data shall be stored for 10 years from the expiry date of the medicinal product series to which the application referred or until the claims expiry or until you have objected to the processing (if the processing is based on legitimate interest of the Controller) or have withdrawn your consent (if the processing is based on consent) whichever occurs first.

[Rights]

12. You have the right to:

- a. access to data concerning you, the right of rectification, erasure, restriction of processing, the right to object to the processing of data;
- b. transfer personal data, i.e. to receive from the controller personal data in a structured, commonly used machine-readable format;
- c. to the extent that the processing of your personal data is based on consent, the right to withdraw consent to the processing of your personal data at any time. The withdrawal of consent shall not affect the lawfulness of the processing carried out on the basis of consent prior to its withdrawal.
- 13. In order to exercise the above rights, you need to contact the Controller or the Data Protection Officer, using the aforementioned contact details (contact details provided above).
- 14. You also have the right to lodge a complaint with a personal data protection supervisory authority (President of the Personal Data Protection Office), if you believe that the data processing violates the GDPR.



DRUG EXPOSURE DURING PREGNANCY – PREGNANCY AND POSTPARTUM FORM

SUPPLEMENTARY INFORMATION TO PARTS A and B OF THE REPORT (WHEN THE PREGNANCY IS COMPLICATED)

Completion date DD/MM/YY		
Source of information	on:	
Pregnant patient	Primary Care Physician	Gynecologist/Obstetrician
Pediatrician	Other (please specify)	
1. Malformations or an Holder	y irregularities detected since the last conta	act with the Marketing Authorization

2. Assessment of child development

past/current diseases	
past hospitalizations	
used drugs	
breast-feeding	YES NO
3. Other important information	

PATIENT INFORMATION REGARDING THE GDPR IS BELOW. If you are a healthcare professional, go to page 18 and read the information regarding the GDPR.

On the basis of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as: "GDPR"), we hereby inform that:

[Controller, data protection officer, contact details]

- The Controller of your personal data is the Marketing Authorization Holder of the medicinal product which is the subject of the notification, i.e.:

 Zakłady Farmaceutyczne POLPHARMA S.A. with its registered office in Starogard Gdański (83-200) at ul. Pelplińska 19. (hereinafter referred to as the "Controller").
- You can contact the Controller in writing to the above addresses. The Controller has appointed a Data Protection Officer, whom you may contact in all matters relating to the personal data protection, by writing to: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) Bobrowiecka 6, 00-728 Warszawa, by sending an e-mail to: dpo@polpharma.com or by telephone on: 22 364 63 11.
- Where an adverse event has occurred following the use of a medicinal product, the adverse event may be reported to the Medical Department, address: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) ul. Bobrowiecka 6, 00 -728 Warszawa, tel.: 22 364 61 00, email: phv@polpharma.com.

[Purpose and legal basis for personal data processing]

4. Your personal data will be processed:

- a. for the purpose necessary for ensuring high standards of quality and safety of medicinal products by Controller and, in particular, monitoring the safety of medicinal products, including the keeping of records of individual adverse events to medicinal products and the reporting of individual adverse events to medicinal products to the competent authorities– on the basis of:
 - data concerning health will be processed pursuant to Article 9(2)(i) of the GDPR, i.e. processing is necessary for reasons related to the public interest in the field of public health in the form of ensuring high standards of quality and safety of medicinal products pursuant to the provisions of law, i.e. pursuant to Article 36e(1) of the Polish Pharmaceutical Law Act;
 - other personal data will be processed pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on the Controller pursuant to Article 36e(1) of the Pharmaceutical Law Act;
- b. contacting the attending physician and obtaining additional information from the attending physician in connection with adverse events to the medicinal product pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on the Controller pursuant to Article 36e(1) of the Pharmaceutical Law Act;
- c. determination, investigation or defence of possible claims between you and the Administrator with regard to health data pursuant to Article 9(2)(b) of the GDPR, i.e. processing is necessary for the determination, investigation or defence of claims; in the case of other personal pursuant to Article 6(1)(f) of the GDPR, i.e. on the basis of the legitimate interest pursued by the Administrator, which is the possibility to pursue claims.
- 5. You will not be subject to automated decision-making, including decisions based on profiling.
- 6. Provision of Your personal data is voluntary.

[Categories of personal data recipients]

- 7. Your personal data may be disclosed to the following entities: attending physician (if consent is granted to contact with the attending physician), employees, IT service providers, providers of consulting and legal services.
- 8. Your personal data may be made available to entities and bodies authorized to process such data under the law, in particular to the President of the Office of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency and other competent authorities of the Member States of the European Union, in which the Controller has obtained a marketing authorisation for a medicinal product.
- 9. The Controller does not intend to transfer your personal data outside the European Economic Area or to an international organisation.

[Personal data storage period]

- 10. Your personal data shall be processed for the period necessary to achieve the purposes for which the data are processed or until an objection is raised (if the processing is based on the legitimate interest of the Controller) or until the withdrawal of consent (if the processing is based on the given consent) depending on which of the events occurs earlier.
- 11. After the expiry of the aforementioned period, personal data shall be stored for 10 years from the expiry date of the medicinal product series to which the application referred or until the claims expiry or until you have objected to the processing (if the processing is based on legitimate interest of the Controller) or have withdrawn your consent (if the processing is based on consent) whichever occurs first.

[Rights]

- 12. You have the right to:
 - a. access to data concerning you, the right of rectification, erasure, restriction of processing, the right to object to the processing of data;
 b. transfer personal data, i.e. to receive from the controller personal data in a structured, commonly used machine-readable format;
 - c. to the extent that the processing of your personal data is based on consent, the right to withdraw consent to the processing of your personal data at any time. The withdrawal of consent shall not affect the lawfulness of the processing carried out on the basis of consent prior to its withdrawal.
- 13. In order to exercise the above rights, you need to contact the Controller or the Data Protection Officer, using the aforementioned contact details (contact details provided above).
- 14. You also have the right to lodge a complaint with a personal data protection supervisory authority (President of the Personal Data Protection Office), if you believe that the data processing violates the GDPR.

HEALTHCARE PROFESSIONAL INFORMATION REGARDING THE GDPR IS BELOW. If you are a Patient, go to page 17 and read the information regarding the GDPR.

On the basis of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, hereinafter referred to as: "GDPR"), we hereby inform that:

[Controller, data protection officer, contact details]

- The Controller of your personal data is the Marketing Authorization Holder of the medicinal product which is the subject of the notification, i.e.:

 Zakłady Farmaceutyczne Polpharma S.A. with its registered office in Starogard Gdański (83-200) at ul. Pelplińska 19 (hereinafter referred to as the "Controller").
- You can contact the Controller in writing to the above addresses. The Controller has appointed a Data Protection Officer, whom you may contact in all matters relating to the personal data protection, by writing to Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw) Bobrowiecka 6, 00-728 Warszawa, by sending an e-mail to: dpo@polpharma.com or by telephone on: 22 364 63 11.
- Where an adverse event has occurred following the use of a medicinal product, the adverse event may be reported to Medical Department, adress: Zakłady Farmaceutyczne POLPHARMA S.A. (office in Warsaw), ul. Bobrowiecka 6, 00 -728 Warszawa, tel.: 22 364 61 00, email: phv@polpharma.com.

[Purpose and legal basis for personal data processing]

4. Your personal data will be processed:

- a. for the purpose necessary for the Controller's ensuring high standards of quality and safety of medicinal products and, in particular, monitoring the safety of medicinal products, including the keeping of records of individual adverse events to medicinal products and the reporting of individual adverse events to medicinal products to the competent authorities– on the basis of:
 - personal data, including the name and surname and address of the medical profession of the person reporting the adverse event of
 a medicinal product pursuant to Article 6(1)(c) of the GDPR, i.e. processing is necessary to fulfil the legal obligation imposed on
 the Controller pursuant to Article 36e(1)(2) and (3) of the Polish Pharmaceutical Law, also pursuant to Article 9 (2) (i) GDPR;
- **b.** determination, investigation or defence of potential claims between you and the Controller basis of Article 6(1)(f) of the GDPR, i.e. on the basis of the legitimate interest pursued by the Controller, which is the possibility to pursue claims.
- 5. You will not be subject to automated decision-making, including decisions based on profiling.
- 6. Provision of Your personal data is obligatory.

[Categories of personal data recipients]

- 7. Your personal data may be disclosed to the following entities: employees, IT service providers, providers of consulting and legal services.
- 8. Your personal data may be made available to entities and bodies authorized to process such data under the law, in particular to the President of the Office of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency and other competent authorities of the Member States of the European Union, in which the Controller has obtained a marketing authorisation for a medicinal product.
- 9. The Controller does not intend to transfer your personal data outside the European Economic Area or to an international organisation.

[Personal data storage period]

- 10. Your personal data shall be processed for the period necessary to achieve the purposes for which the data are processed or until an objection is raised (if the processing is based on the legitimate interest of the Controller) or until the withdrawal of consent (if the processing is based on the given consent) depending on which of the events occurs earlier.
- 11. After the expiry of the aforementioned period, personal data shall be stored for 10 years from the expiry date of the medicinal product series to which the application referred or until the claims expiry or until you have objected to the processing (if the processing is based on legitimate interest of the Controller) or have withdrawn your consent (if the processing is based on consent) whichever occurs first.

[Rights]

12. You have the right to:

- a. access to data concerning you, the right of rectification, erasure, restriction of processing, the right to object to the processing of data;
- b. transfer personal data, i.e. to receive from the controller personal data in a structured, commonly used machine-readable format;
- c. to the extent that the processing of your personal data is based on consent, the right to withdraw consent to the processing of your personal data at any time. The withdrawal of consent shall not affect the lawfulness of the processing carried out on the basis of consent prior to its withdrawal.
- 13. In order to exercise the above rights, you need to contact the Controller or the Data Protection Officer, using the aforementioned contact details (contact details provided above).
- 14. You also have the right to lodge a complaint with a personal data protection supervisory authority (President of the Personal Data Protection Office), if you believe that the data processing violates the GDPR.